Inspection and Quarantine Department, The College of Medical Technology, Shanghai University of Medicine & Health Sciences, 279 Zhouzhu Road, 201318 Shanghai, PR China; The Genius Medicine Consortium (TGMC), Shanghai, PR China.
The Genius Medicine Consortium (TGMC), Shanghai, PR China; Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, PR China.
Gene. 2019 Dec 30;721:144097. doi: 10.1016/j.gene.2019.144097. Epub 2019 Sep 4.
Polo-like kinase 1 (PLK1) is a potential prognostic marker in colorectal cancer (CRC). Nevertheless, the clinicopathological and prognostic roles of PLK1 in CRC are still undefined. Therefore, we performed a meta-analysis to investigate the clinicopathological and prognostic relevance of PLK1 expression in CRC patients.
Studies published between 2003 and 2016 were selected for the meta-analysis based on an electronic literature search (PubMed, EMBASE and Chinese databases). Studies that investigated the clinicopathological and prognostic impacts of PLK1 expression in CRC patients were included for this analysis.
Eleven studies that enrolled 1147 CRC patients were included in our meta-analysis. The effect of PLK1 level on overall survival (OS) was reported in five studies, which included 702 patients. Ten studies investigated the clinicopathological role of PLK1 expression in CRC patients. Consequently, PLK1 overexpression was associated with poorer OS in CRC patients. Furthermore, the results revealed that higher PLK1 levels were also observed in CRC tissues compared with that of normal colorectal tissues. In addition, this meta-analysis also revealed positive correlations between PLK1 upregulation and lymph node metastasis or invasion. PLK1 overexpression was significantly correlated with advanced TNM stages and higher Dukes stages.
This meta-analysis strongly supports the hypothesis that PLK1 might serve as an important factor in evaluating the biological behavior and prognosis of CRC.
丝氨酸/苏氨酸激酶 Polo-like 激酶 1（PLK1）是结直肠癌（CRC）的一个潜在预后标志物。然而，PLK1 在 CRC 中的临床病理和预后作用仍未明确。因此，我们进行了一项荟萃分析，以研究 PLK1 在 CRC 患者中的表达与临床病理和预后的相关性。
根据电子文献检索（PubMed、EMBASE 和中文数据库），选择 2003 年至 2016 年期间发表的研究进行荟萃分析。纳入研究 PLK1 表达对 CRC 患者临床病理和预后影响的研究进行分析。
荟萃分析纳入了 11 项共纳入 1147 例 CRC 患者的研究。5 项研究报告了 PLK1 水平对总生存期（OS）的影响，共纳入 702 例患者。10 项研究调查了 PLK1 表达在 CRC 患者中的临床病理作用。结果表明，PLK1 过表达与 CRC 患者的 OS 较差相关。此外，该荟萃分析还表明，CRC 组织中 PLK1 水平高于正常结直肠组织。此外，这种荟萃分析还揭示了 PLK1 上调与淋巴结转移或浸润之间存在正相关。PLK1 过表达与较晚的 TNM 分期和较高的 Dukes 分期显著相关。
这项荟萃分析强烈支持了 PLK1 可能是评估 CRC 生物学行为和预后的重要因素的假说。
